42 results about "Intestinal permeability" patented technology

We are disclosing derivatives of 5-hydroxylated polymethoxyflavones. The derivatives offer enhanced oral bioavailability and improved intestinal permeability. The derivatives of the invention release the biologically active 5-hydroxylated polymethoxyflavones that are activated by chemical or enzymatic processes in the GI Tract. The derivatives are constructed as bioreversible prodrugs containing the bioactive molecules covalently linked with lipids like fatty acids, glycerides or phospholipids. The derivatives are useful against inflammatory conditions and aging. Formulations including the derivatives are also disclosed.

This invention belongs to the field of feed preparation technology, specifically disclosing a feed composition suitable for Aohan donkeys and its application in fattening. The feed composition comprises the following raw materials in parts by weight: 25-35 parts of compound fermented product, 0.5-2 parts of camellia extract, 30-40 parts of corn stalks, and 5-10 parts of cottonseed meal. This invention discloses a feed composition suitable for Aohan donkeys and its application in fattening. This feed composition can increase the body weight and average daily weight gain of Aohan donkeys, reduce intestinal permeability indicators, improve intestinal barrier function, promote the growth and development of Aohan donkeys, and improve the meat quality of Aohan donkeys.

The invention relates to the technical field of medicines for treating intestinal ischemia-reperfusion injury, and discloses a medicine for treating intestinal ischemia-reperfusion injury and a preparation method thereof. Comprising 10 to 25 parts of rosmarinic acid, 5 to 15 parts of betaine, 3 to 10 parts of glutamine, 10 to 25 parts of salvianolic acid B, 5 to 15 parts of astragaloside, 3 to 10 parts of ginsenoside Rg1, 2 to 8 parts of curcumin, 5 to 12 parts of ophiopogon japonicus polysaccharide, 2 to 6 parts of notoginsenoside R1, 3 to 7 parts of total flavonoids of oldenlandia diffusa and 4 to 9 parts of angelica sinensis polysaccharide. The medicine disclosed by the invention can be used for relieving intestinal edema, repairing oxidative injury, clearing excessive ROS, improving SOD activity, blocking oxidative stress injury, inhibiting epithelial cell apoptosis, reducing intestinal permeability and maintaining mucous membrane integrity, and has an excellent treatment effect on intestinal ischemia reperfusion injury.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.

The invention discloses an in-vitro drug intestinal permeability determination method based on a high-flux barrier chip, and belongs to the technical field of microfluidics and organ chips. The high-flux barrier chip adopts a three-layer structural design of a pore plate layer, a porous membrane layer and a channel layer; the porous membrane not only realizes physical separation of the pore plate layer and the channel layer, but also undertakes the core function of interlayer substance exchange, and by matching with a gravity flow driving system provided by the swing table, the fluid dynamic characteristics in the chip are guaranteed. The hole pitch of the chip is strictly matched with the standard of a commercialized pore plate, and the chip can be directly compatible with various conventional analytical instruments and has good universality. The method is suitable for determining the intestinal permeability of the passive transport compound which can be absorbed by intestinal cells. Compared with the prior art, the human intestinal cells are adopted to construct the chip model, animal experiments do not need to be carried out, related ethical disputes are thoroughly avoided, the whole operation process is simple and easy to implement, and the detection time is greatly shortened.

The invention discloses a compound and application thereof in preparation of a medicine for treating Alzheimer disease. The invention provides a method for constructing a disease animal model by using N-oleoyldopamine (OLDA) and application of the model in drug screening and animal experiment research. The animal model comprises at least one animal model of neurodegenerative diseases, intestinal permeability diseases and inflammatory diseases. According to the application, based on OLDA, it is found that the compound has new application in the aspects of neurodegenerative diseases, intestinal permeability diseases and inflammatory diseases, and based on OLDA, the compound which plays a certain role in treating the diseases is screened out.

This invention discloses the application of a composition in the preparation of foods or medicines that reduce blood lead levels, belonging to the field of food or pharmaceutical applications. The composition is for improving intestinal microecology, comprising inulin, galactooligosaccharides, polydextrose, and water-insoluble dietary fiber, wherein the weight ratio of inulin, galactooligosaccharides, polydextrose, and water-insoluble dietary fiber is 25:25:20:30, and the composition is taken immediately after being dissolved in warm water before meals. This invention, through the rational combination of water-insoluble dietary fiber and functional polysaccharides, adjusts the release rate of nutrients in the intestine, slows down digestion, absorbs and eliminates toxic substances from food, reduces intestinal permeability, and simultaneously possesses the functions of water absorption and swelling, gradient adhesion, mechanical isolation, mesh adsorption, ion exchange, and microbial regulation, providing a favorable environment and food for the growth of intestinal microorganisms, and effectively reducing blood endotoxins and blood lead levels, enhancing immunity, and preventing chronic diseases.

The invention discloses a feed additive for improving pathogen resistance and intestinal injury of high-fat fed fishes and application of the feed additive, and belongs to the technical field of fish feed. The feed additive is indole-3-propionic acid, and the application of the feed additive is that IPA is added into a high-fat feed according to the addition amount of 20-160 mg / kg. Experiments find that IPA with different concentrations can significantly improve the aeromonas hydrophila infection resistance of tilapia fed with high fat, enhance the intestinal immune enzyme activity, improve the intestinal permeability, enhance the intestinal antioxidant ability and relieve intestinal inflammation. The IPA disclosed by the invention can be used as a novel feed additive, can effectively relieve the problems of pathogen resistance reduction and intestinal injury of high-fat fed fishes, and has a good application prospect.

The present invention relates to a Lactobacillus reuteri, and use, composition, drug and food thereof. The Lactobacillus reuteri has an accession number of CGMCC No. 21577, can improve intestinal flora disorder, reduce intestinal injury, improve intestinal permeability and promote immune system recovery, and has effects of treating or preventing allergic reactions of nervous system-related diseases such as autism, hyperactivity, tics, depression, etc.

The use of a probiotic, in particular an Enterococcus faecium strain named SF68, for the treatment of disorders characterized by alterations of the intestinal mucosa, particularly inflammations associated with altered intestinal permeability is described.

Disclosed herein are compositions and methods for treating, improving, reducing, or ameliorating a disease or condition associated with intestinal permeability in a subject wherein the disease or condition associate with intestinal permeability is selected from the group consisting of irritable bowel syndrome-bile acid diarrhea (IBS-BAD). Method disclosed herein may also include providing to a subject a composition comprising at least one fiber source and an effective amount of N-trans-caffeoyltyramine and N-trans-feruloyltyramine.

The invention belongs to the technical field of biomedicine, and particularly relates to application of polypeptide in preparation of a medicine for treating radioactive intestinal injury. The polypeptide sequence provided by the invention is Thr-Met-Val-Asp-Ala, is called TMVAD small peptide for short, and is subjected to N-terminal acetylation and C-terminal amidation modification. Results of embodiments prove that mouse animal experiments prove that the TMVAD small peptide has a radiation protection effect in an X-ray induced mouse radioactive intestinal injury model, and can significantly improve the survival rate of irradiated mice, reduce the inflammatory factor level of the irradiated mice, improve the intestinal permeability, promote the regeneration of crypt cells and repair the intestinal mucosal barrier. Compared with the existing symptomatic support treatment or non-specific polypeptide control, the TMVAD small peptide has a remarkable radiation protection effect, so that the TMVAD small peptide can be used as a novel and effective radiation protection and radioactive intestinal injury treatment medicine for clinical treatment of radioactive intestinal injury.

This invention relates to the field of pharmaceutical technology, specifically to the application of porcine deoxycholic acid (HDCA) in the preparation of a drug for alleviating colitis. The dosage of HDCA is 50-200 mg / kg body weight / day. The colitis referred to is DSS-induced colitis, inflammatory bowel disease, or ulcerative colitis. Administration is by gavage. The drug alleviates colitis by promoting the proliferation of intestinal stem cells and / or repairing intestinal barrier function. This method can reverse the decrease in food intake and body weight in mice under DSS, reduce their disease activity index, and alleviate the problem of DSS-induced colon shortening in mice; simultaneously, HDCA also promotes the proliferation of intestinal stem cells, repairs intestinal permeability, and alleviates DSS-induced damage to the intestinal mucosal barrier function in mice. It can inhibit the expression of intestinal inflammation-related genes in mice, alleviating inflammatory complications. It helps to reshape the intestinal flora of mice, especially promoting Akkermansia colonization and alleviating intestinal barrier damage.

The present invention relates to a Lactobacillus reuteri, and use, composition, drug and food thereof. The Lactobacillus reuteri has an accession number of CGMCC No. 21577, can improve intestinal flora disorder, reduce intestinal injury, improve intestinal permeability and promote immune system recovery, and has effects of treating or preventing allergic reactions of nervous system-related diseases such as autism, hyperactivity, tics, depression, etc.

This invention relates to the application of *Bifidobacterium longum* BL21 in the preparation of formulations to alleviate multi-organ damage induced by cisplatin chemotherapy, namely, a novel microbial strategy for preventing or alleviating multi-organ damage induced by cisplatin chemotherapy. This invention creatively discovers that *Bifidobacterium longum* BL21 can alleviate kidney damage, intestinal damage, and bone marrow suppression without interfering with the antitumor activity of cisplatin. Specifically, it can reverse the increase in serum creatinine and blood urea nitrogen levels caused by cisplatin chemotherapy, reverse the increase in inflammatory factor levels in kidney tissue caused by cisplatin chemotherapy, and alleviate oxidative stress damage in kidney tissue caused by cisplatin chemotherapy; it can reverse the increase in intestinal permeability caused by cisplatin chemotherapy, reverse the downregulation of intestinal tight junction protein expression caused by cisplatin chemotherapy, reverse the increase in serum endotoxin levels caused by cisplatin chemotherapy, and reverse the decrease in beneficial intestinal bacteria caused by cisplatin chemotherapy; it can improve hematopoietic dysfunction caused by cisplatin chemotherapy and restore white blood cell count.

The invention relates to lactobacillus amylovorans and an application thereof in intestinal diseases, the lactobacillus amylovorans (LA) is named as lactobacillus amylovorans QC1H, is preserved in China Center for Type Culture Collection on March 28, 2023, and has a preservation number of CCTCC NO: M2023427, the lactobacillus amylovorans and / or a fermentation product thereof can significantly improve the ratio of mouse intestinal villus length to crypt depth, and the lactobacillus amylovorans and / or the fermentation product thereof can significantly improve the intestinal villus length and crypt depth of mice. The compound has the advantages of reducing mouse ileum enteritis factor expression, improving ileum tight junction protein expression and reducing intestinal permeability, and has important application significance and value in preparation of a therapeutic agent for preventing and treating enteritis caused by aflatoxin B1 (AFB1).

The present application relates to the field of biological medicine and functional food, and discloses a kind of nutrition composition based on marine shrimp peptide for anti-obesity and improving metabolic syndrome;Including: Chinese tube whip shrimp peptide active component and pharmaceutically acceptable adjuvant, the Chinese tube whip shrimp meat protein is used as raw material, and the Chinese tube whip shrimp meat protein is prepared by alkaline protease enzymolysis, and the Chinese tube whip shrimp meat protein contains peptide segment with molecular weight less than 1 kDa, and APPPPP, HPPPP and MPLPP can be detected.The pharmaceutical composition can reduce the weight and fat tissue weight under the state of obesity, improve dyslipidemia, abnormal liver function and liver steatosis, reduce oxidative stress level, improve intestinal mucosal barrier damage and intestinal permeability increase, and regulate intestinal flora structure change.The active component in the present application is clear in origin, and the preparation process is clear, has the synergistic effect from lipid metabolism regulation, liver protection to intestinal barrier improvement, and can be used for preparing medicine for preventing or treating obesity and improving metabolic syndrome.

The application discloses a kind of film type L-arginine-alpha-ketoglutarate salt sustained-release particles and its preparation method and application.The sustained-release particles include internal core material and external wall material, internal core material is L-arginine-alpha-ketoglutarate salt, external wall material is homogeneous complex matrix of stearic acid and sodium alginate, and the mass ratio of core material and wall material is 7:3 to 8:2.The sustained-release particles are obtained by stearic acid-sodium alginate complex wall material cold spray coating L-arginine-alpha-ketoglutarate salt, realize the synergistic effect of gastric acid tolerance and intestinal target release.Under 0.75%-1.00% additive dose, the sustained-release particles can significantly repair fish intestinal physical barrier, up-regulate tight junction protein and oligopeptide transporter expression, reduce serum intestinal permeability markers, and simultaneously activate muscle mTOR signaling pathway, promote collagen deposition, reduce drip loss rate, and comprehensively improve fish intestinal health and muscle quality.

The invention belongs to the technical field of markers, and particularly relates to application of a diagnostic marker for diarrhea of lambs in a lactation period. The invention provides application of a diagnostic marker for diagnosing diarrhea of lambs in the lactation period in preparation of a reagent or a kit for diagnosing and predicting diarrhea of lambs in the lactation period. The diagnostic marker is selected from at least one of the following metabolic pathways: a glycerophospholipid metabolic pathway, a fatty acid metabolic pathway and an amino acid metabolic pathway. The diagnostic marker provided by the invention can comprehensively analyze the health condition of the lambs based on detection data of three dimensions of serum inflammatory factors, intestinal permeability markers and fecal metabonomics, can accurately predict potential diarrhea risks at the stage that the lambs do not present clinical symptoms of diarrhea, creates favorable opportunities for timely intervention, and has a good application prospect. The occurrence and diffusion of diarrhea diseases are effectively prevented.

The application discloses a cyclosporine A solid self-emulsifying drug composition and a preparation method thereof, and the drug composition comprises, in percentage by mass, 60-75% of a carrier material, 16.7-33.3% of a compatibility adjusting material, and the rest of cyclosporine A, and the sum of the mass percentages of all raw materials is 100%. The application is innovative in process from two aspects of selection of a compatibility adjusting material and a drug loading mode by developing a brand-new pre-molecularization-co-extrusion mode, and a ternary amorphous solid dispersion of cyclosporine A with strong compatibility and high stability is designed. The application fully utilizes the dissolution advantage of the amorphous solid dispersion technology, promotes the release of cyclosporine A, and simultaneously, due to the formation of a self-assembled sub-micro emulsion system, the intestinal permeability of cyclosporine A is significantly improved, and therefore, the application is a new preparation strategy which is safe and effective, green and environmentally-friendly, and has application prospects.

The invention discloses a rumen ball strain and application thereof, belongs to the technical field of biology, and aims to solve the problems of side effects of antibiotic treatment, limitation of total fecal fungus transplantation and the limitation of insufficiency of probiotics in treatment of sepsis-related lung injury in the existing detection technology. The invention provides a ruminococcus sp. Strain Rum-307, which is separated from excrement of healthy people, has a unique gene sequence, and can be rapidly colonized after antibiotic treatment, reduce intestinal permeability and prevent endotoxin transfer; by regulating CD4 + T cell subtypes, the level of proinflammatory factors (TNF-alpha and IL-6) is reduced, the anti-inflammatory factor (IL-10) is improved, and immune balance is achieved. In a CLP sepsis model, the Rum-307 can significantly improve the wet / dry ratio, the pathological score and the survival rate of the lung. The strain Rum 307 can be prepared into capsules, oral liquid and other dosage forms, is easy to produce, is suitable for treating sepsis, acute respiratory distress syndrome, intestinal sepsis and other diseases, and has remarkable clinical and commercial prospects.

The present invention provides probiotic compositions and methods for improving animal health. The probiotic compositions include one or more isolated strains of Lactobacillus reuteri which colonizes the gastrointestinal tract to increase the health of an animal, including to alleviate the effects of chronic alcohol consumption, leaky gut, increased intestinal permeability and inflammation and treat or prevent alcohol-associated intestinal dysbiosis, leaky gut, increased intestinal permeability and inflammation, including intestinal inflammation associated with inflammatory bowel disease.

Disclosed in the present invention is the use of a water extract of Amomi fructus and / or a vanillic acid in the preparation of a drug for preventing and / or treating preeclampsia. Further disclosed in the present invention is the use of the water extract of Amomi fructus and / or the vanillic acid in the preparation of a drug for preventing and / or treating hypertension caused by preeclampsia, or a drug for preventing and / or treating proteinuria caused by preeclampsia, or a drug for reversing a reduction in placental weight caused by preeclampsia, or a drug for restoring fetal intrauterine growth restrictions caused by preeclampsia, or a drug for restoring pathological damage to placental tissue or placental dysfunction caused by preeclampsia, or a drug for reversing the reduction in placental efficiency caused by preeclampsia, or a drug for repairing colonic barrier damage or increased intestinal permeability caused by preeclampsia, or a drug for enriching the intestinal tract of a patient with preeclampsia with Bifidobacterium bifidum. The present invention overcomes the limitations of current drugs for treating preeclampsia which exhibit limited single therapeutic effects and gastrointestinal adverse reactions.

This invention discloses a class of dendritic lipopeptide molecules that promote the oral absorption of macromolecular drugs, their preparation method, and applications. The dendritic lipopeptide molecules are formed by combining a hydrophilic head and a hydrophobic tail. The hydrophilic head consists of lysine and glutamic acid linked by amide bonds, while the hydrophobic tail is composed of organic carbon chains or fluorinated chains. The oral absorption enhancer used in this invention exhibits amphoteric characteristics, possessing excellent anti-protein adsorption capabilities, superior mucus penetration and small intestinal permeability, and good biocompatibility due to its amino acid element construction. The oral absorption enhancer used in this invention can cross multiple barriers, including the mucus layer and intestinal epithelial cells, without opening tight junctions, facilitating efficient and safe oral encapsulation and delivery of proteins.

The invention relates to the technical field of functional food processing, in particular to a method for enhancing intestinal barrier function regulating activity of galactooligosaccharide based on collagen peptide Maillard coupling and application of the method. According to the method for enhancing the intestinal barrier regulating activity of the galactooligosaccharide based on Maillard coupling of the collagen peptide, provided by the invention, the biological effect of the galactooligosaccharide in the aspect of regulating the intestinal barrier function can be remarkably improved; meanwhile, the obtained Maillard conjugate has remarkable advantages in the aspects of promoting mucous secretion of goblet cells, up-regulating expression of tight junction proteins ZO-1 and Occludin and reducing intestinal permeability. The method provided by the invention is simple and convenient to operate, industrialization is easy to realize, the obtained product can be used as a functional component related to intestinal health to be applied to the fields of food, functional food and the like, and the application value of galactooligosaccharide can be effectively improved.

The present invention relates to a biomarker composition for diagnosing psoriasis, comprising a Clostridium leptum strain as an active ingredient. It has been confirmed that the relative intestinal abundance of the strain is significantly reduced in a psoriasis patient group in comparison to that of a normal group, and the strain is effective in alleviating psoriasis symptoms and improving intestinal permeability, and thus can be effectively used as a composition for diagnosing, preventing, treating, or alleviating psoriasis.

This invention relates to the fields of nanotechnology, food science, and biomedicine, specifically to a zein-pectin composite nanoparticle loaded with naringin, its preparation method, and its application. The method includes the following steps: (1) dissolving zein and naringin in an alcohol-water solution to obtain a first solution; dissolving pectin in water to obtain a second solution; (2) adding the first solution to the second solution under stirring conditions. The average diameter of the composite nanoparticles conforms to the size range of nanodelivery systems, exhibiting excellent colloidal stability even under extreme environmental conditions; it also possesses good intestinal permeability and improved gastrointestinal bioavailability, and demonstrates potent antioxidant activity in vitro; furthermore, in cell models, the composite nanoparticles effectively alleviated oxidative stress, reduced free fatty acid-induced hepatocyte damage, and regulated lipid metabolism.

The invention discloses application of ziziphus jujuba in preparation of a medicine for regulating intestinal permeability, and belongs to the technical field of medicines. The application refers to the application of the ziziphus jujube, the extract of the ziziphus jujube or the pharmaceutical composition of the ziziphus jujube in preparation of a medicine for regulating intestinal permeability, a medicine for preventing and treating intestinal barrier function injury, a medicine for treating intestinal leakage and a medicine for preventing and treating related diseases of the intestinal leakage. In an immunity investigation process, the invention accidentally finds that the intestinal permeability of rats which are molded by cyclophosphamide and have low immunity is increased, and the intestinal barrier function is severely damaged. After intestinal permeability increase and inflammatory injury caused by low immunity of cyclophosphamide molding, the Chinese ixeris dates can efficiently remove intestinal inflammation, repair intestinal villus and crypt form, remarkably reduce DAO, ET, LPS and LN levels of rats with low immunity of cyclophosphamide molding, and realize rapid reduction of intestinal permeability, repair of intestinal leakage and treatment of intestinal barrier function injury. The influence of body immunosuppression on intestinal lesions is reversed.

The application discloses application of a hydrogel-coated human amniotic epithelial stem cell and exosomes thereof to preparation of a drug for improving intestinal inflammation, and intestinal inflammation symptoms of a mouse are significantly reduced through anal injection, which is manifested in faster recovery of body weight, lower disease activity score, and significant reduction of intestinal permeability increase caused by UC. Intestinal epithelial function reconstruction is promoted, which is manifested in intestinal permeability improvement, intestinal epithelial integrity improvement, inflammation reaction reduction, intestinal epithelial tissue regeneration promotion, and apoptosis reduction. According to the above results, the human amniotic epithelial stem cell and the exosomes thereof can be applied to UC treatment in combination with a biomaterial. The method has a wide prospect in clinical application of UC treatment.